A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. (March 2018)

• Record Type: Journal Article
• Authors: Tsang, Erica S; de Haan, Marie; Eigl, Bernhard J
• Is Part Of: Journal of oncology pharmacy practice. Volume 24:Number 2(2018)
• Page Start: 143
• Page End: 145
• Publication Date: 2018-03
• Subjects: Prostate cancer -- enzalutamide -- dialysis; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155216689381
• Languages: English
• ISSNs: 1078-1552

Abstract

Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials.